Lonza collaborates Cristal Therapeutics and McSAF to expand Bioconjugates offering

Through the new agreements, Cristal Therapeutics and McSAF will gain access to Lonza’s integrated bioconjugates offering and will be able to leverage Lonza’s expertise in developing and manufacturing bioconjugates

GeneQuantum and WuXi XDC enter into strategic cooperation to empower innovative bioconjugates development

Lonza and Singzyme to accelerate development of Bioconjugates

Through the collaboration, Lonza will gain access to Singzyme’s enzymatic conjugation platform enabling the site-specific binding of payloads with peptidic linkers to proteins of interest

GeneQuantum Healthcare's two bioconjugate drugs approved for clinical trials in Australia

They are GQ1005, an ADC with an excellent bystander killing effect, and GQ1007, a first-in-class antibody-immune-agonist-conjugate (AIAC) both with global intellectual property rights

Orion secures license to Abzena’s next-generation cancer antibody

The antibody was designed and developed at Abzena’s Cambridge, UK,

Lonza receives Swissmedic approval for Biologics drug product filling line in Stein

New filling line approval supports delivery of integrated, end-to-end solutions across the entire biologics and bioconjugates value chain

Lilly to build $5 billion manufacturing facility in Virginia

This marks the first of four new U.S. manufacturing sites that Lilly plans to announce this year

Mycenax and Spera forge alliance to streamline ADC drug substance

Lonza reports 19% growth in sales in H1

Upgrades 2025 full-year CDMO sales and margin outlook

WuXi XDC announces mechanical completion of Singapore site

The site, spanning approximately 25,000 square meters, is expected to commence operations by the end of 2025